drugset / Trial / NCT05373433
To Evaluate SSD8432/Ritonavir in Adults With COVID-19
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, phase II/III clinical study to evaluate the efficacy and safety of SSD8432 in combination with ritonavir in adult subjects with mild/common COVID-19.
Timeline
- Start
- 2022-05-26
- Primary completion
- 2023-05-31
- Completion
- 2023-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | simnotrelvir | Small molecule | 750 mg | — |